# Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia

> **NCT00399464** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1177 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** alfuzosin

## Key facts

- **NCT ID:** NCT00399464
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 1177 (ACTUAL)
- **Last updated:** 2009-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399464, "Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00399464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*